Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds

Total Page:16

File Type:pdf, Size:1020Kb

Load more

molecules

Review

Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds

Danuta Wojcieszyn´ska , Ariel Marchlewicz and Urszula Guzik *

Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiellon´ska 28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67

Academic Editors: Urszula Guzik and Danuta Wojcieszyn´ska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020

ꢀꢁꢂꢀꢃꢄꢅꢆꢇ

ꢀꢁꢂꢃꢄꢅꢆ

Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased

interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of

enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms

1. Introduction

The development of modern tools for the separation and identification of chemical substances

has drawn attention to the so-called micropollution of the environment. Many of these contaminants

belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate

in the tissue of living organisms and can adversely affect them [

include pharmaceuticals, the presence of which are not only found in hospital or municipal sewage but

also in Arctic water or drinking water [ ]. In many laboratories, new methods for the degradation

1]. Substances meeting these criteria

1,2

of these compounds are being developed, with the use of microorganisms that have an increased

potential for the degradation of these compounds. Biological treatment is a promising technology due

to its low cost and reduced energy requirements [

these microorganisms in the complex microbial consortia of wastewater treatment plants [

more and more attention has been paid to immobilized systems, in which these strains are protected by binding them to a carrier [ ]. The use of microorganism immobilization in the drug’s biodegradation

  • 3
  • ,4

]. However, the main problem is the survival of

5

]. Hence,

  • 4
  • ,6,7

not only protects them from harmful environmental conditions, but also leads to an increase in the intensity of the biotransformation processes as a result of the local thickening of the biomass and a higher tolerance of the bacterial cells to these pharmaceuticals [

4

,7]. The intensive development of

immobilization methods has led to the discovery of many carriers and immobilization techniques [

  • 7
  • ,8

].

The new techniques differ in the level of difficulty of the procedure used, cost-effectiveness, efficiency

of the processes carried out in the immobilized systems and the usefulness in the immobilization of the

microorganisms. For this reason, the purpose of this work is to review the achievements to date in the

Molecules 2020, 25, 4473

2 of 25

field of using immobilized systems in the endocrine disrupting compounds biodegradation processes.

This will systematize the existing knowledge about the subject and indicate the advantages and

disadvantages of the methods used, as well as the needs and perspectives for the further development

of immobilization methods.

2. Endocrine Disrupting Compounds (EDCs) in the Environment and Associated Risks

Endocrine disrupting compounds (EDCs) are natural or synthetic substances that, when introduced into the environment, affect the endocrine and homeostatic system of non-target organisms by disabling

their communication and response to environmental stimuli. These include estrogens- natural and synthetic female and male hormones that play an important role in both the reproductive and the

non-reproductive systems [

considered to be the strongest among the endocrine factors in the environment [10]. Synthetic estrogens

have been divided into steroidal, such as 17 -ethynylestradiol and 3-methyl ether of ethynylestradiol,

used as ingredients of birth control pills, and nonsteroidal estrogens such as diethylstilbestrol used to

prevent miscarriages [ 11]. Human use of the latter was banned in 1972 due to its negative effects,

3,6,9]. Estrone, estriol and 17β-estradiol are natural estrogens. The latter is

α

3

,7,

however, it is still used in China as a growth promotor for terrestrial livestock or fish [11]. The presence

of estrogens has been reported in many aquatic environments (Table 1).

Table 1. Occurrence of EDCs in the environment.
EDCs

Estrone

Concentration

10.4 ng/L

  • Occurrence
  • Sampling Period

Spring to autumn Spring to autumn Spring to autumn December to May December to May December to May
May

References

[4]
Leca River (Portugal) Leca River (Portugal) Leca River (Portugal) Wuluo River
(Taiwan) Wuluo River
(Taiwan) Wuluo River
(Taiwan)
17β-Estradiol
Estriol

  • 5.9 ng/L
  • [4]

  • 4.4 ng/L
  • [4]

  • Estrone
  • 1.27 ng/L
  • [12]

[12] [12] [13] [13] [14] [14] [15] [16] [16] [17] [17] [18]
17β-Estradiol
Estriol
313.60 ng/L 210.00 ng/L 40–117 ng/L
9.78–151 ng/L
0.076–0.233 ng/L
0.68 ng/L
Surface water of Taihu Lake, China Sediments of Taihu
Lake, China Lake Balaton, Hungary River Zala, Hungary
Yangtze estuary,
China
Themi River, Tanzania
Kalansanan River,
Malaysia
Fenholloway River,
USA
Fenholloway River,
USA
17β-Estradiol 17β-Estradiol 17β-Estradiol
May No data

  • 17α
  • -Ethynyl-estradiol

Estrogen
No data
3.22–20.61 ng/L
20.4–439 ng/L
16,689 ng/L
40 ng/L
Four seasons

  • March
  • Progesterone

  • Progesterone
  • No data

Androstenedione Progesterone

May and December May and December

High rainy periods
2060 ng/L
Atibaia River,
Brazil

17α-Ethynyl-estradiol 981–4390 ng/L

Molecules 2020, 25, 4473

3 of 25

Table 1. Cont.

  • EDCs
  • Concentration

17–501 ng/L

  • Occurrence
  • Sampling Period

Dry winter period High rainy periods Dry winter period

References

[18]
Atibaia River,
Brazil
Atibaia River,
Brazil
Atibaia River,
Brazil

17α-Ethynyl-estradiol

  • 17β-Estradiol
  • 464–6806 ng/L

106–2273 ng/L
[18]

  • 17β-Estradiol
  • [18]

High rainy periods and dry winter period
Atibaia River,
Brazil

  • Estrone
  • 16 ng/L
  • [18]

Atibaia River,
Brazil
Atibaia River,
Brazil
Atibaia River,
Brazil
Atibaia River,
Brazil
Progesterone Progesterone Levonorgestrel Levonorgestrel
20 ng/L
20–195 ng/L
19 ng/L
High rainy periods Dry winter period High rainy periods Dry winter period
[18] [18] [18]

  • [18]
  • 19–663 ng/L

High rainy periods and dry winter period
Atibaia River,
Brazil

  • 4-Octylphenol
  • 21 ng/L
  • [18]

High rainy periods and dry winter period
Atibaia River,
Brazil

  • 4-Nonylphenol
  • 18 ng/L
  • [18]

Testosterone Testosterone Estrogen Estrogen Estriol
1.9–2.7 ng/L 1.0–3.8 ng/L 0.6–2.2 ng/L 1.2–3.4 ng/L 0.9–1.8 ng/L 0.9–2.9 ng/L

Lower Jordan River Lower Jordan River Lower Jordan River Lower Jordan River Lower Jordan River Lower Jordan River

May October May October May October
[19] [19] [19] [19] [19]

  • [19]
  • Estriol

One of the main sources of estrogens in a highly urbanized environment is urine and faeces getting

into wastewater. It has been shown that annually 33 and 49 tonnes of estrogen excreted from farms

in the European Union and the United States, respectively, are released into the environment [12,20].

In human and animal organisms, estrogens are usually hydroxylated or conjugated with glucuronide

or sulfate hence these forms most often get into wastewater. It is estimated that about 90% of urine

estrogens are in the form of conjugates. Most estrogen conjugates are more polar than parent molecules,

so they can be more mobile in the environment. Despite the fact that conjugates have low estrogenic

potential, they can be chemically or enzymatically hydrolysed to active forms in the environment. For example, the Escherichia coli strain KCTC 2571 has β-glucuronidase, which cleaves glucuronide

moieties, releasing free estrogen [20,21].

As a result of the operation of sewage treatment plants, 19–94% of estrogens are biodegraded

and biotransformed. Typically, concentrations in the range of 1–3 ng/L are observed in the effluents

from treatment plants [3]. Although these compounds occur in the environment in concentrations of ng/L, it is known that they can have a strong negative impact in amounts below 1 ng/L because

they have a high affinity for nuclear estrogen receptors. This biological activity can lead to low levels

of estrogen in the environment causing endocrine disorders in the wildlife population. Negative

effects on development, sex differentiation, reproduction of different animal species and production

of vitellogenin have been documented [ negative impact on the sexual behaviour of frogs in suburban areas in the United States have been

observed [12]. In addition, it has been shown that 17 -estradiol, at concentrations of 0.1–1 ng/L, causes

3,4,7,11,12]. Intersexual disorders in fish in Europe, and a

β

reproductive disorders in aquatic animals. Disrupting in the development, spawning and fertility of Japanese medaka (Oryzias latipes) was showed at low estrogen concentrations [20]. An increase in osteoblast activity was also detected in fish such as goldfish and wrasse, which resulted in the

Molecules 2020, 25, 4473

4 of 25

mobilization and mineralization of fish scales [22]. The presence of this compound in the environment

may cause disturbances in the secretion of endogenous gonadal sex hormone in humans and reduce

sperm production, as well as increase the incidence of cancer [6]. In addition, it has been observed

that often the response to estrogens is dependent on the age of the organisms. For instance, adults of

common roach showed a slight response to the presence of estrogens, while exposure to hormonal

compounds during the embryonic period caused 100% feminization in fish. In toxicological studies at

various developmental stages, Atlantic salmon showed a higher level of vitellogenin mRNA in the presence of EDCs in all stages, except in embryos. In addition, embryos were only sensitive to the

highest levels of 17α-ethynylestradiol while the remaining stages responded to the intermediate and

highest doses not only of 17α-ethynylestradiol, but also 17β-estradiol, and nonylphenol. Moreover,

fry have been shown to be the most sensitive of the salmon life stage on EDCs [23]. Czarny et al. [24]

showed a dose-dependent effect of estrogens on the growth of cyanobacteria Microcystis aeruginosa. Concentrations below 1 mg/L did not affect the growth of cyanobacteria, whereas concentrations of hormones above 10 mg/L inhibited their growth. This is due to the phenomenon of hormesis.

Low hormone concentrations activate the repair functions of cyanobacteria and induce the activity of

proteins involved in them. Higher concentrations damage the maintenance and repair functions of cells. It was also observed that the effect of chronic toxicity depended on the hormone used and it decreased according to the series: 17-α-ethynylestradiol > progesterone > 17ß-estradiol > 5-pregnen-3β-ol-20-one > testosterone > estrone> levonorgestrel > estriol. Moreover, the hormone mixture caused a significant

increase in toxicity compared to the same concentrations of individual hormones. The range of EC50

values obtained for the mixture of hormones and individual hormones were 56.66–166.83 mg/L and

88.92–355.15 mg/L, respectively (according to the EU classification, pollutants with EC50 values of

10–100 mg/L are harmful to aquatic organisms). The negative impact of hormones on cyanobacteria is

connected with the rapid penetration of hormones into cells and the impact on photosynthetic activity

by interfering with the flow of electrons through the photosystem II [24]. A significant increase in the

toxicity of the mixture compared to individual substances may translate into more serious ecological

effects. This observation is all the more important because of the environment where we usually deal

with mixtures of hormones. Moreover, estrogens can accumulate in the food chain and the effects may appear in the next generation, threatening the health of the human population [4,11,24]. Also,

the World Health Organization classified estrogens as group 1 carcinogens and some of their catechol

metabolites such as 4-hydroxyestrone are also carcinogens [12,25].

Another group of endocrine substances that can be found in the environment are androgens.

Like estrogens they can interfere with the normal functioning of the endocrine system of non-target

organisms in trace concentration and they have many sources from which they get into the water, and due to filtration they also get into underground water. One of the most commonly identified androgens in the environment is testosterone, its presence in the environment may cause a high

percentage of males in the aquatic environment, appearance of male secondary sex characteristics in

female fish, inhibition of vitellogenin induction, reduction of reproductive capacity and masculinization

in mammals [26]. For example, defeminisation has been observed in fathead minnows that have been

exposed to wastewater from cattle farms [27]. Moreover, it has been showed that male Atlantic salmon

exhibit an odorant response to testosterone at extremely low concentration (0.003 ng/L) [28].

There are also substances in the environment that disturb the action of endogenous compounds

due to the similarity of their structure to hormones (chemicals mimic hormones), such as bisphenol

A, 4-nonylphenol, parabens and phthalate, as well as antibacterial triclosan [29,30]. Moreover, some mycotoxins, such as zearalenone produced by several Fusarium spp., have strong estrogenic activity [31]. These compounds are resistant to microbiological degradation and their duration in sediments can be up to 40 years and, similar to hormonal substances, sometimes they can be food

contaminants and thus, they can cause reproductive and developmental disorders of aquatic animals

and humans [29,31]. Kriszt et al. [31] showed that zearalenone significantly increased the uterus weight

in a dose dependent manner and upregulated complement component 2, calbindin-3 expression,

Molecules 2020, 25, 4473

5 of 25

and decreased apelin and aquaporin 5 mRNA levels. This is due to the high affinity of zearalenone

for estrogen receptors. Moreover, this compound and its metabolite α-zearalenol stimulate the

proliferation of MCF-7 human adenocarcinoma cells [31]. Nonylphenol may cause various disorders of

the male reproductive system, such as a reduction of testicle size and decrease of sperm production in

Oncorhynchus mykiss. This mimic hormone was also observed to induce the proliferation of the human

breast cancer cell line [32]. Due to the prevalence of endocrine compounds and other pharmaceuticals

in the environment and their possible negative effect on non-target organisms, more and more attention

is being paid to the methods of their removal from the environment.

3. Microbiological Degradation of EDCs

In developed countries, where the problem of endocrine substances is the greatest, sewage treatment plants play a key role in their removal. Organisms involved in the removal of estrogens

from the environment include bacteria, as well as fungi and microalgae (Figure 1) [11].

Figure 1. The main mechanisms for removing EDCs [3,9,26,30].

Bacteria that degrade these hormones belong to genera such as Bacillus, Virgibacillus,

Novosphingobium, Rhodococcus, Acinetobacter, Pseudomonas, Sphingomonas, Enterobacter, Klebsiella, Aeromonas, Comamonas, Thauera, Deinococcus, Stenotrophomonas and cyanobacteria [ 28 31 33 39]. Raphidocelis subcapitata, Chlorella vulgaris, Chlorococcus and Scenedesmus quadricauda

belong to algae capable of removing hormones [11 26 40 41]. Fungi from genus Trichoderma,

3,4,6,7,10,12,25,

  • ,
  • ,

  • ,
  • ,
  • ,

Trametes, Phanerochaete, Pleurotus, Aspergillus, Lentinula, Drechslera, Curvularia, Penicillium, Acremonium,

Fusarium, Gibberella, Beauvaria, Doaratomyces, Scopulariopsis, Chaetomidium, Thielavia, Neurospora, Absidia,

Cunninghamella, Actinomucor, Rhizopus, Phycomyces, Mortierella, Circinella and Ganoderma (Table 2) were

also described as being capable of hormone biodegradation/biotransformation [22,30,42–46].

Molecules 2020, 25, 4473

6 of 25

Table 2. Microorganisms engaged in EDCs biodegradation/biotransformation.

  • Organism
  • EDCs
  • Dose
  • Eciency [%]
  • References

Virgibacillus halotolerans
Bacillus flexus
Bacillus licheniformis

Novosphingobium sp. ARI-1

17β-estradiol 17β-estradiol 17β-estradiol estrone
5 mg/L 5 mg/L 5 mg/L
1.75 µg/L 1.52 µg/L 0.71 µg/L 30 mg/L 2 mg/L
100 100 100
80.43
100
94.76
94
[3] [3] [3] [4] [4] [4] [6] [7] [7] estriol
17β-estradiol 17β-estradiol
17α-ethynylestradiol 17α-ethynylestradiol

Rhodococcus sp. JX-2 Rhodococcus zopfii Pseudomonas putida F1
Acinetobacter sp.

86.5

  • 73.8
  • 0.5 mg/L

  • 17β-estradiol
  • 40 mg/L
  • 90
  • [10]

DSSKY-A-001

Acinetobacter sp. LHJ1 Acinetobacter sp. BP8 Acinetobacter sp. BP10

Novosphingobium sp. SLCC

Sphingomonas sp. KC8

17β-estradiol 17β-estradiol 17β-estradiol estrone
0.5 mg/L 1.8 mg/L
5 mg/L
100 100 100 no data
100 100
[10] [10] [10] [12] [25] [25] [25] [28]
1 mM

  • estrone
  • 0.05 mg/L

0.05 mg/L 0.05 mg/L
1 mM
17β-estradiol testosterone testosterone
100

  • no data
  • Thauera sp. GDN1

Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals

    Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals

    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
  • Pheromone Advantage Review Examining Dr. Virgil Amend's

    Pheromone Advantage Review Examining Dr. Virgil Amend's

    Pheromone Advantage: Review Examining Dr. Virgil Amend’s Pheromone Cologne Product Released Pheromone Advantage reviews have been popping up all over the Internet and GentlemensUniversity.com reveals the truth about this cologne that claims it makes it so much easier to attract the opposite gender. (PRWEB) February 08, 2014 Pheromone Advantage that claims people can amplify their sexual appeal to the opposite sex and even intimidate others from the same sex by simply spritzing some of the pheromone cologne on has caught the attention of GentlemensUniversity.com’s Stan Stevenson, prompting an investigative review. “Our Pheromone Advantage review shows that it is a pheromone cologne product developed by Dr. Virgil Amend. It triggers emotions and sexual attraction without the opposite sex ever realizing that they are actually being influenced by pheromones,” reports Stevenson. “Most other pheromone scents contain very small amounts of pheromones, certainly not enough to have much of an impact on the opposite sex. Pheromone Advantage comes in two variants, one meant to attract men, and the other for targeting women. Each variant is formulated accordingly with the correct pheromones with a large enough concentration, so they can’t easily be washed away or masked.” Pheromone Advantage for attracting women is formulated with Androstenone, Androstenol, and Androstadienone. Produced by both men and women, although Androstenone is considered to be a predominantly male pheromone, it gives off a good strong vibe akin to that of an alpha male. Androstenol helps the wearer seem less intimidating and more approachable, and helps elevate the mood of a woman. Pheromone Advantage for attracting men contains Copulins, Estratetraenol, and Androstenol.
  • Estrogen Actions Throughout the Brain

    Estrogen Actions Throughout the Brain

    Estrogen Actions Throughout the Brain BRUCE MCEWEN Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, New York 10021 ABSTRACT Besides affecting the hypothalamus and other brain areas related to reproduction, ovarian steroids have widespread effects throughout the brain, on serotonin pathways, catecholaminergic neurons, and the basal forebrain cholinergic system as well as the hippocampal formation, a brain region involved in spatial and declarative memory. Thus, ovarian steroids have measurable effects on affective state as well as cognition, with implications for dementia. Two actions are discussed in this review; both appear to involve a combination of genomic and nongenomic actions of ovarian hormones. First, regulation of the serotonergic system appears to be linked to the presence of estrogen- and progestin-sensitive neurons in the midbrain raphe as well as possibly nongenomic actions in brain areas to which serotonin neurons project their axons. Second, ovarian hormones regulate synapse turnover in the CA1 region of the hippocampus during the 4- to 5-day estrous cycle of the female rat. Formation of new excitatory synapses is induced by estradiol and involves N-methyl-D-aspartate (NMDA) receptors, whereas downregulation of these synapses involves intracellular progestin receptors. A new, rapid method of radioimmunocytochemistry has made possible the demonstration of synapse formation by labeling and quantifying the specific synaptic and dendritic molecules involved. Although NMDA receptor activation is required for synapse formation, inhibitory interneurons may play a pivotal role as they express nuclear estrogen receptor-alpha (ER␣). It is also likely that estrogens may locally regulate events at the sites of synaptic contact in the excitatory pyramidal neurons where the synapses form.
  • Part I Biopharmaceuticals

    Part I Biopharmaceuticals

    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
  • Evolution of the Bile Salt Nuclear Receptor FXR in Vertebrates

    Evolution of the Bile Salt Nuclear Receptor FXR in Vertebrates

    Supplemental Material can be found at: http://www.jlr.org/cgi/content/full/M800138-JLR200/DC1 Evolution of the bile salt nuclear receptor FXR in vertebrates † † † †† †† Erica J. Reschly,* Ni Ai, Sean Ekins, ,§,** William J. Welsh, Lee R. Hagey, Alan F. Hofmann, and Matthew D. Krasowski1,* † Department of Pathology,* University of Pittsburgh, Pittsburgh, PA 15261; Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ 08854; Collaborations in Chemistry,§ Jenkintown, PA 19046; Department of Pharmaceutical Sciences,** †† University of Maryland, Baltimore, MD 21202; and Department of Medicine, University of California-San Diego, San Diego, CA 92093-0063 Abstract Bile salts, the major end metabolites of cho- Bile salts are water-soluble, amphipathic end metabolites lesterol, vary significantly in structure across vertebrate of cholesterol that facilitate intestinal absorption of lipids species, suggesting that nuclear receptors binding these (1), enhance proteolytic cleavage of dietary proteins (2), Downloaded from molecules may show adaptive evolutionary changes. We com- and have potent antimicrobial activity in the small intestine pared across species the bile salt specificity of the major (3). In addition, bile salt signaling via nuclear hormone re- transcriptional regulator of bile salt synthesis, the farnesoid X receptor (FXR). We found that FXRs have changed speci- ceptors (NHRs) is important for bile salt homeostasis (4). ficity for primary bile salts across species by altering the Bile salts have not been detected in invertebrate animals. shape and size of the ligand binding pocket. In particular, In contrast to steroid hormones and vitamins, whose struc- the ligand binding pockets of sea lamprey (Petromyzon marinus) tures tend to be strongly conserved, bile salts exhibit www.jlr.org and zebrafish (Danio rerio) FXRs, as predicted by homology marked structural diversity across species (5–7).
  • Illinois Medicaid Preferred Drug List

    Illinois Medicaid Preferred Drug List

    Illinois Medicaid Preferred Drug List Effective January 1, 2020 (Updated January 27, 2020) ▪ The Preferred Drug List (PDL) has products listed in groups by drug class, drug name, dosage form, and PDL status ▪ Multi-source drugs are listed by both brand and generic names when applicable ▪ ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪ Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪ Budesonide: Prior authorization NOT required for participants age 7 years and under ▪ Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪ Antipsychotics: Prior authorization required for participants under 8 years of age and long-term care residents ▪ For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Page 1 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM ADHD / ANTI-NARCOLEPSY AGENTS : AMPHETAMINES ADZENYS ER SUER NON_PREFERRED AMPHETAMINE ER SUER NON_PREFERRED DYANAVEL XR SUER NON_PREFERRED ADZENYS XR-ODT TBED NON_PREFERRED AMPHETAMINE SULFATE TABS NON_PREFERRED EVEKEO TABS NON_PREFERRED EVEKEO ODT TBDP NON_PREFERRED DEXEDRINE CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE ER CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE SOLN NON_PREFERRED PROCENTRA SOLN NON_PREFERRED DEXTROAMPHETAMINE SULFATE TABS NON_PREFERRED ZENZEDI TABS NON_PREFERRED VYVANSE CAPS PREFERRED VYVANSE CHEW PREFERRED
  • Health Effects of Progestins Contained in Cocs, with A

    Health Effects of Progestins Contained in Cocs, with A

    A PHACTICAL JOURNAL FOR NUHSE PRACTITIONEn5 I i - 1- November 2007 The Official Journal of NPWHj- A 7 .-. Vol. G, No. 11 A Peer-Reviewed Journal &$ Health Effects of Progestins Contained in t COCs, with a -.'P Focus on Norgestimate- -.-I. 21 ? NPWH 2007 ' Annual Conference Abstracts HEALTH EFFECTS OF PROLESTINS CONTAINED IN COCs, WITH A FOGUS ON NORGESTIMATE by Penelope M. Bosarge, MSN, WHNP ased on interviews with more Nurse practitioners (NPs) and their reproductive-aged than 7600 female adolescents and women aged 15 to 44 patients face numerous challenges, particularly when it years, more than 98% who have comes to choosing a method of birth control. If a combined ever had sexual intercourse have used at least one contraceptive oral contraceptive (COC) is judged to be an appropriate meth~d.~The leading method of contraception in the United choice for a given woman, then her NP will need to select a States in 2002 was the Pill, used particular product from among many that are available. by 11.6 million women, and the second leading method was Among the various COC brands on the market, several female sterilization, used by 10.3 million women.2The condom contain norgestimate (NGM), a progestin introduced in was the third-leading method, 1992. Fvteen years of clinical use of NGM-containing used by about 9 million women and their partners. The condom COCs, as well as continued scientz$c investigations of these is the leading method at first intercourse, but the Pill is the products, support their efficacy, safety, and tolerability leading method among women (ie, these products have minimal androgenic and estrogenic younger than 30 yearse2 effects and provide excellent cycle control).
  • 1,25-Dihydroxyvitamin D3-Induced Genes in Osteoblasts

    1,25-Dihydroxyvitamin D3-Induced Genes in Osteoblasts

    1,25-DIHYDROXYVITAMIN D3-INDUCED GENES IN OSTEOBLASTS: UNCOVERING NEW FUNCTIONS FOR MENINGIOMA 1 AND SEMAPHORIN 3B IN SKELETAL PHYSIOLOGY by XIAOXUE ZHANG Submitted in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Thesis advisor: Paul N. MacDonald Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY May 2009 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________ candidate for the ______________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. I dedicate this thesis to my mother and father for their lifelong love, encouragement and sacrifice TABLE OF CONTENTS Table of Contents ii List of Tables iii List of Figures iv Acknowledgements vii Abbreviations x Abstract xiii Chapter I Introduction 1 Chapter II Meningioma 1 (MN1) is a 1,25-dihydroxyvitamin D3- 44 induced transcription coactivator that promotes osteoblast proliferation, motility, differentiation, and function Chapter III Semaphorin 3B (SEMA3B) is a 1,25- 108 dihydroxyvitamin D3-induced gene in osteoblasts that promotes
  • (12) Patent Application Publication (10) Pub. No.: US 2011/001412.6 A1 Evans Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/001412.6 A1 Evans Et Al

    US 2011 0014126A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/001412.6 A1 Evans et al. (43) Pub. Date: Jan. 20, 2011 (54) USE OF VITAMIND RECEPTORAGONISTS (60) Provisional application No. 60/985,972, filed on Nov. AND PRECURSORS TO TREAT FIBROSS 6, 2007. (76) Inventors: Ronald M. Evans, La Jolla, CA Publication Classification (US); Michael Downes, San Diego, CA (US); Christopher Liddle, (51) Int. Cl. New South Wales (AU): A 6LX 3/59 (2006.01) Nanthakumar Subramaniam, A6IPL/I6 (2006.01) New South Wales (AU); Caroline CI2O 1/02 (2006.01) Flora Samer, Geneva (CH) A61R 49/00 (2006.01) CI2N 5/071 (2010.01) Correspondence Address: (52) U.S. Cl. ............. 424/9.2: 514/167; 435/29: 435/375 KLARQUIST SPARKMAN, LLP 121 S.W. SALMONSTREET, SUITE 1600 (57) ABSTRACT PORTLAND, OR 97204 (US) This application relates to methods of treating, preventing, (21) Appl. No.: 12/772,981 and ameliorating fibrosis, such as fibrosis of the liver. In particular, the application relates to methods of using a vita (22) Filed: May 3, 2010 min D receptor agonist (Such as vitamin D. Vitamin Dana logs, vitamin D precursors, and vitamin D receptor agonists Related U.S. Application Data precursors) for the treatment of liver fibrosis. Also disclosed (63) Continuation-in-part of application No. 12/266,513, are methods for screening for agents that treat, prevent, and filed on Nov. 6, 2008. ameliorate fibrosis. Stellate Cells Liver RR1,3 AR, ERa ERR1,2,3, AR, ERa CNF GR, MR CNF RARa, GR, MR NF4g Rab NF4ag RARa,b, NOR1 a, RH1 TRa,b WDR NURR1 NOR1 RORa,b,g RORag CAR Receptor SF-1 FXRa,b FXRa,b epissertoup.
  • Sex Pheromones and Their Role in Vertebrate Reproduction

    Sex Pheromones and Their Role in Vertebrate Reproduction

    Intraspecific chemical communication in vertebrates with special attention to sex pheromones Robert van den Hurk Pheromone Information Centre, Brugakker 5895, 3704 MX Zeist, The Netherlands Pheromone Information Centre, Zeist, The Netherlands. Correspondence address: Dr. R. van den Hurk, Brugakker 5895, 3704 MX Zeist. E-mail address: [email protected] Intraspecific chemical communication in vertebrates with special attention to sex pheromones (191 pp). NUR-code: 922. ISBN: 978-90-77713-78-5. © 2011 by R. van den Hurk. Second edition This book is an updated edition from a previous book entitled: ‘Intraspecific chemical communication in vertebrates with special attention to its role in reproduction, © 2007 by R. van den Hurk. ISBN: 978-90-393-4500-9. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the author. Printed by EZbook.nl 2 Contents Abbreviations 5 Preface 6 Abstract 7 Introduction 8 Sex pheromones in fishes 14 Gobies 14 Zebrafish 15 African catfish 21 Goldfish 26 Other fish species 30 Reproduction and nonolfactory sensory cues 35 Sex pheromones in amphibians 37 Red-bellied newt 37 Sword-tailed newt 37 Plethodontid salamanders 38 Ocoee salamander 38 Korean salamander 39 Magnificent tree frog (Litoria splendida) and mountain chicken frog (Leptodactylus fallax) 39 Other amphibian species 39 Sex pheromones in reptiles 42 Lizards
  • Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S

    Evidence Synthesis Number 180 Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Heidi D. Nelson, MD, MPH Rongwei Fu, PhD Bernadette Zakher, MBBS Marian McDonagh, PharmD Miranda Pappas, MA L.B. Miller, BA Lucy Stillman, BS AHRQ Publication No. 19-05249-EF-1 January 2019 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.